Neuzafy (filgrastim)

Where it stands

Neuzafy (filgrastim), from CuraTeQ Biologics (Malta) Limited, is at the opinion stage in the EU. The records show a CHMP positive opinion dated 2026-10-15, flagged as an official milestone. No approval date is recorded, so the product is not yet authorised in the EU on the information provided.

The records give the indication as treatment of neutropenia in adults and children. The therapeutic areas are listed as neutropenia, febrile neutropenia and chemotherapy-induced febrile neutropenia. The records do not give the full wording of the indication, the dosing or any restrictions, so the exact scope of the label cannot be assessed here.

The next step is the European Commission decision. The records show an expected EC decision date of 2026-12-21. This is an estimate, calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. It is not an official date.

Regulatory pathway and designations

The only designation recorded is Biosimilar. In the EU, a biosimilar opinion is based on a demonstration of similarity to a reference biological medicine. The records do not name the reference product or describe the comparability data, so no conclusions can be drawn about the evidence package.

Under the centralised procedure, the CHMP opinion is a scientific recommendation. The marketing authorisation becomes legally effective only when the European Commission adopts its decision, normally within about 67 days of the opinion. The 2026-12-21 date follows that standard timeframe and is not a confirmed milestone.

The records list the same substance elsewhere. In the EU, Nylaspeg, Filgrastim Hexal, Zarzio, Cavoley and Ratiograstim are all authorised. In the US, Armlupeg is approved. Neuzafy would therefore enter an EU market that already has several authorised products with this substance. The records do not say whether these are all filgrastim biosimilars or whether they share formulation or presentation with Neuzafy. They also contain no US filing information for Neuzafy itself.

Safety and pharmacovigilance

The records contain no safety data for Neuzafy. They include no adverse event profile, risk management plan details, conditions of authorisation or post-authorisation commitments. No safety conclusions can be drawn from them.

As general procedure, EU medicines, including biosimilars, are authorised with a risk management plan and are subject to routine pharmacovigilance after approval. Biologics must also be traceable by product name and batch number. Whether Neuzafy has any product-specific requirements will only be clear from the EPAR and product information once published.

What to watch

The key event is the EC decision, estimated for 2026-12-21. Because that date is an estimate, a slightly earlier or later adoption would not be unusual. Confirmation will come from the Commission's decision and the Union Register.

After the decision, watch for publication of the EPAR and product information. These should show the final indication wording, the reference product and any pharmacovigilance conditions, none of which are in the current records.

Also watch for the launch timing and the product's position among the five authorised EU products with the same substance. The records contain no information on launch plans or market position, so none can be inferred.